ALNY Alnylam Pharmaceuticals Inc.

82.07
-2.82  -3%
Previous Close 84.89
Open 85.06
Price To Book 6.71
Market Cap 8735296490
Shares 106,437,145
Volume 1,376,402
Short Ratio
Av. Daily Volume 745,170

NewsSee all news

  1. Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
  2. Is Alnylam Pharmaceuticals a Buy Now?
  3. Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
  4. Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
  5. Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Fitusiran
Hemophilia A and B
Phase 3 trial met primary endpoint. Rolling NDA has been initiated.
Givosiran
Acute hepatic porphyrias
Phase 3 data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Phase 1/2 data due 2019.
ALN-HBV02 (VIR-2218))
Chronic hepatitis B virus (HBV)
Phase 3 data due late-2019.
Lumasiran (ALN-GO1) ILLUMINATE-A
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 2 trial to be initiated.
ALN-CC5 (cemdisiran)
IgA nephropathy
Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Hemophilia
Phase 3 trial enrolling - noted December 6, 2018.
ALN-TTRsc02 - HELIOS-A
ATTR amyloidosis
Phase 3 sata due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 data due 2019.
ALN-AAT02
alpha-1 anti-trypsin deficiency-associated liver disease
Phase 3 trial initiation announced April 15, 2019 with initial data due mid-2020.
Lumasiran (ALN-GO1) ILLUMINATE-B
Primary Hyperoxaluria Type 1

Latest News

  1. Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
  2. Is Alnylam Pharmaceuticals a Buy Now?
  3. Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
  4. Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
  5. Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
  6. Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
  7. 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
  8. Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
  9. See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
  10. Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
  11. Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics
  12. Regeneron forays into gene-silencing therapies with Alnylam tie-up
  13. Alnylam trades partner Sanofi for Regeneron in $800M deal
  14. What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory?
  15. Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
  16. Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
  17. Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration
  18. 2 Biotechs With Big Dates in April
  19. Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress™